- Home
- TRVI vs ACP Comparison
TRVI vs ACP Comparison
Compare TRVI & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- ACP
- Stock Information
- Founded
- TRVI 2011
- ACP 2010
- Country
- TRVI United States
- ACP United States
- Employees
- TRVI N/A
- ACP N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- TRVI Health Care
- ACP Finance
- Exchange
- TRVI Nasdaq
- ACP Nasdaq
- Market Cap
- TRVI 725.7M
- ACP 737.8M
- IPO Year
- TRVI 2019
- ACP N/A
- Fundamental
- Price
- TRVI $6.89
- ACP $5.96
- Analyst Decision
- TRVI Strong Buy
- ACP
- Analyst Count
- TRVI 9
- ACP 0
- Target Price
- TRVI $19.94
- ACP N/A
- AVG Volume (30 Days)
- TRVI 1.6M
- ACP 337.9K
- Earning Date
- TRVI 08-07-2025
- ACP 01-01-0001
- Dividend Yield
- TRVI N/A
- ACP 17.79%
- EPS Growth
- TRVI N/A
- ACP N/A
- EPS
- TRVI N/A
- ACP N/A
- Revenue
- TRVI N/A
- ACP N/A
- Revenue This Year
- TRVI N/A
- ACP N/A
- Revenue Next Year
- TRVI N/A
- ACP N/A
- P/E Ratio
- TRVI N/A
- ACP N/A
- Revenue Growth
- TRVI N/A
- ACP N/A
- 52 Week Low
- TRVI $2.36
- ACP $5.55
- 52 Week High
- TRVI $7.48
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- TRVI 64.54
- ACP 61.36
- Support Level
- TRVI $5.41
- ACP $5.89
- Resistance Level
- TRVI $6.08
- ACP $5.98
- Average True Range (ATR)
- TRVI 0.32
- ACP 0.04
- MACD
- TRVI 0.14
- ACP 0.00
- Stochastic Oscillator
- TRVI 89.91
- ACP 87.50
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.